HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Core Insights - HUTCHMED is presenting new and updated data on its compounds savolitinib, fruquintinib, and surufatinib at the AACR Annual Meeting 2025, highlighting ongoing research and development efforts in oncology [1][2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [11]. - The company has successfully marketed three medicines in China, with its first drug also approved in the US, Europe, and Japan [11]. Product Information - Savolitinib: An oral, selective MET tyrosine kinase inhibitor developed in collaboration with AstraZeneca, approved in China for treating advanced or metastatic NSCLC with MET exon 14 skipping alterations [5][6]. - Fruquintinib: Undergoing clinical development for various tumor types, including colorectal cancer, and is being studied in combination with other therapies [2][5]. - Surufatinib: Currently in clinical trials for advanced neuroendocrine tumors and other cancers, with ongoing studies to assess its efficacy in combination with other treatments [2][3]. Clinical Trials and Research - The SAVANNAH study is evaluating the combination of savolitinib and osimertinib in NSCLC patients who have progressed after EGFR TKI treatment, with promising results leading to further Phase III trials [7][9]. - The SACHI trial has met its primary endpoint of progression-free survival, supporting the combination of savolitinib and TAGRISSO for specific NSCLC patients [9][10]. - The SAFFRON trial is assessing the efficacy of savolitinib plus TAGRISSO against platinum-based chemotherapy in a similar patient population [10]. Market Context - Lung cancer remains the leading cause of cancer death globally, with a significant patient population in China, where over a third of the world's lung cancer patients reside [4]. - Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases, with a notable prevalence of EGFR mutations and MET alterations among patients [4].